The frequency of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) is approximately 3%–5% [ [1] ], and the administration of ALK tyrosine kinase inhibitors has achieved impressive outcomes. Apart from EML4–ALK, various ALK fusion partner genes have recently been identified [ [2] ]. In this case, we report a novel PNPT1 (polyribonucleotide nucleotidyl transferase 1)–ALK fusion responding to crizotinib in a patient with lung adenocarcinoma. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.05.014
Authors: Linling Jin, Yanli Wang, Si Li, Dongsheng Chen, Xin Zhao
